IN THE CLAIMS:

Amend the claims as follows:

Claims 16-32. (Canceled)

33. (New) A drug composition comprising at least one nitrogeneous polycyclic derivative of the following formula



wherein

m = 1, 2 or 3

Rn is anyone of R1, R2, R3 and R4, which are identical or different and represent H or represent one or several radicals and are selected in the group comprising OH, an alkyl radical, O-alkyl group, NH_2, NH-alkyl, N(R5, R6), or an halogen selected in the group consisting of F, Cl, Br, the alkyl being in said radical or groups, a C1-C6 alkyl, R_5 and R_6 being a C1-C3 alkyl group,

Y forms a phenyl group with both pyridines, optionally ortho-substituted by a substituent R7, or ortho-disubstituted by R7 and R8, said substituents being identical or different, and selected in the group comprising an alkyl radical, O-alkyl group, NH_2, NH-alkyl, N(R5, R6), or an halogen selected between the group consisting of F, Cl, Br, the alkyl being in said radical or groups a C1-C6 alkyl and R_5 and R_6 are as above defined

or

Y represents a group $-(CH_2)_{m1}-W-(CH_2)_{m2}-$, with m1 and m2 being 0, 1 or 2 and W being a group CH_2, CH(R9), O, or N(R10), R9 and R10 being a C1-C3 alkyl radical, or H,

Z is a linking arm of formula $-A-(CH_2)_n-U-(CH_2)_n-A-$

wherein

A being O or NH, and

U being selected in the group comprising $(CH_2)_{n1}$, CHN(R5,R6), CHCOOH, CHOH

with n being a number from 1 to 6, preferably from 2 to 4, and n1 being 0 or 1,

and the complexes thereof with transition metals, particularly with copper, zinc or iron.

34. (New) The composition according to claim 33, wherein said derivative includes 2 cyclic moieties.

35. (New) The composition according to claim 33, wherein said derivative includes 3 cyclic moieties.

36. (New) The composition according to claim 33, wherein said derivative includes 4 cyclic moieties.

37. (New) The composition according to claim 33, wherein, in said derivative, the cyclic moiety consists of a Phen moiety.

38. (New) The composition according to claim 37, wherein said derivative is a polycyclic Phen having formula (II)



39. (New) The composition according to claims 33, in a form for treating degenerative diseases selected from Alzheimer disease, Parkinson disease, and Huntington disease.

40. (New) The composition according to claim 33, wherein the composition comprises an effective amount of at least one derivative with a pharmaceutical inert vehicle.

41. (New) The composition of claim 40, in an oral, intramuscular or intravenous administerable form.

42. (New) The composition according to claim 41, in the form of tablets, pills, capsules, drops, patch, or spray.

43. (New) The composition according to claim 41, in the form of an injectionible solution produced from sterile or sterilisable solution, or suspension or emulsion.

44. (New) A method for preparing the derivatives of claim 33, comprising reacting

- a dihydroxy bipyridine derivative of formula (III)



with

- a ditosyl derivative of formula (IV)



wherein Rn, Y and Z are as defined in claim 33.

45. (New) The method of claim 44, wherein the reaction is carried out with high dilution conditions.

46. (New) The method of claim 44, comprising the use of cesium carbonate.

47. (New) A method of chelating transition metals comprising contacting a composition of claim 33 with a material comprising said metals.

48. (New) A method of treating a neurodegenerative disease comprising administering a composition of claim 33 to an individual in need of said treatment.

49. (New) The method of claim 48 wherein said disease is selected from Alzheimers disease, Parkinsons disease and Huntingtons disease.